Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Merck Foundation

- PMLiVE

Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households

Lagevrio is already approved to treat certain patients with COVID-19 in several markets

- PMLiVE

Merck reports positive results for Keytruda combination in phase 3 gastric cancer trial

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Merck KGaA and Aqilion AB partner in potential €960m deal

The companies will work together to develop small molecule inhibitors of the TAK1 protein

- PMLiVE

Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer

Endometrial cancer is the sixth most common cancer in women worldwide

- PMLiVE

Eli Lilly and EVA Pharma collaborate to enhance insulin access in Africa

The African-made insulin products are expected to reach one million people per year by 2030

- PMLiVE

Merck and Moderna’s personalised cancer vaccine shows promise in high-risk melanoma patients

The vaccine in combination with Keytruda reduced the risk of recurrence or death by 44%

- PMLiVE

Merck’s sotatercept shows promise as pulmonary arterial hypertension add-on treatment in phase 3 trial

The study met its primary endpoint of a clinically meaningful improvement in six-minute walk distance

- PMLiVE

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment

Patients will now be able to access immunotherapy at an earlier stage in their treatment pathway

- PMLiVE

Merck granted fast track designation by FDA for end-stage renal disease therapy

MK-2060 is currently being investigated in a phase 2 study to evaluate the efficacy and safety of two different doses

- PMLiVE

Merck and Orna agree on deal worth $3.5bn for RNA technology

The companies will work together to develop proprietary circular RNA technology

- PMLiVE

AstraZeneca and Merck’s Lynparza combination therapy receives FDA priority review in first-line prostate cancer

Prostate cancer is the second most common cancer in male patients in the US, projected to cause around 35,000 deaths in 2022

- PMLiVE

AstraZeneca and Daiichi Sankyo announce results for lung cancer therapy

Initial results for the combination therapy – with Merck’s Keytruda – show an overall response rate of 37% in patients with non-small cell lung cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links